Vitruvias Therapeutics Recalls 30 mg Thyroid Tablets Over Superpotency, See If You Have the Affected Lot

If you take Thyroid, USP 30 mg tablets, check your bottle right now. Vitruvias Therapeutics recalled one lot — No. 504950 — after testing confirmed the pills could be stronger than labeled. Taking superpotent thyroid medication can push you into hyperthyroidism. The company sold 1,955 of the 3,655 units it released, and it hasn’t reported any injuries yet. Here’s exactly how to check if your bottle is one of them.

Vitruvias Thyroid Tablets Recall — Key Facts

Field	Detail
Company	Vitruvias Therapeutics, Inc. (Auburn, Alabama)
Product	Thyroid Tablets, USP 30 mg
NDC Number	69680-166-00
Recalled Lot	504950
Expiration Date	9/30/2026
Reason for Recall	Potential for the product to be superpotent
Units Released / Sold	3,655 released / 1,955 sold
Distribution Dates	Jan. 31, 2025 – Sept. 30, 2025
Distribution Scope	Nationwide, to Vitruvias’ direct accounts
Reported Adverse Events	None reported as of the recall announcement
Company Announcement Date	August 21, 2026
FDA Publish Date	August 24, 2026
Last Updated	August 26, 2026

Why Vitruvias Recalled This Thyroid Medication

Thyroid, USP is a natural preparation made from porcine thyroid glands, combining levothyroxine and liothyronine to treat hypothyroidism, or an underactive thyroid. Testing on Lot 504950 confirmed the tablets could be superpotent — stronger than the labeled 30 mg dose. That matters because a hypothyroidism drug that’s too strong doesn’t just fail to help; it can flip your body into the opposite problem. Taking more thyroid hormone than your body needs, especially for weeks or months without knowing it, is a slow-building risk rather than a one-time scare.

What Superpotent Thyroid Tablets Can Do to Your Body

Consuming superpotent thyroid tablets can cause hyperthyroidism, or an overactive thyroid. That can show up as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, a rapid heart rate, or heart rhythm disturbances. Three groups face the highest risk: elderly patients, who are more likely to see cardiac complications from excess thyroid hormone; pregnant women, where overtreatment is linked to a higher rate of premature delivery and low birth weight; and infants, where overtreatment can affect growth and development. The longer someone unknowingly takes a superpotent dose, the more these risks compound.

That’s the real danger here — not a single bad pill, but months of gradual overdosing that a patient might mistake for something else entirely.

Is Your Thyroid Medication Part of This Recall?

Here’s exactly how to know if this recall includes you.

• Check your prescription bottle for NDC 69680-166-00 and Lot 504950
• Anyone who filled a prescription for Vitruvias Thyroid Tablets, USP 30 mg between January 31, 2025, and September 30, 2025
• Bottles with an expiration date of September 30, 2026, printed on the label
• Other lot numbers of Vitruvias Thyroid Tablets are not part of this recall — only Lot 504950 is affected
• Other dosage strengths (not 30 mg) are not covered by this recall

Vitruvias Thyroid Tablets Recall — Nationwide Coverage

This is a federal recall, so it applies no matter what state you live in. Lot 504950 went out to Vitruvias’ direct accounts across the country, not to one region or pharmacy chain.

What Should You Do Right Now?

1. Check your bottle for Lot 504950 and NDC 69680-166-00. If it doesn’t match, this recall doesn’t apply to you.
2. Do not stop taking the medication on your own. Suddenly stopping thyroid medication carries its own risks — contact your healthcare provider first for guidance or a replacement prescription.
3. Call your doctor or pharmacist to arrange a replacement and ask whether you should be tested for thyroid hormone levels.
4. Watch for hyperthyroidism symptoms — unexplained weight loss, rapid heartbeat, chest pain, heat intolerance, or nervousness — and seek medical attention if they appear.
5. Contact Vitruvias Therapeutics directly with questions at [email protected] or (256) 239-9373, Monday through Friday, 9 a.m. to 5 p.m. CT.
6. Report any adverse reaction to the FDA’s MedWatch program online or by calling 1-800-332-1088 for a reporting form.

Takes about 10 minutes to check your bottle and make the call — worth doing today if you or a family member takes this medication.

Were You Harmed by These Tablets?

Vitruvias Therapeutics hasn’t received any reports of adverse events tied to this recall so far, and no lawsuit has been filed over it as of this writing. That could change if patients come forward with documented harm. If you or a family member took Thyroid Tablets from Lot 504950 and experienced hyperthyroidism symptoms, cardiac problems, or pregnancy complications afterward, a product liability attorney can help you understand whether you have grounds for a claim and what documentation you’d need — medical records, pharmacy receipts, and dates of use all matter here.

Vitruvias Thyroid Tablets Recall — Frequently Asked Questions

How do I know if my thyroid medication is part of the Vitruvias recall?

 Check your bottle for NDC 69680-166-00 and Lot 504950. Only that specific lot of Thyroid Tablets, USP 30 mg is affected — other lots and other dosage strengths are not part of this recall.

Should I stop taking my thyroid medication if it’s from the recalled lot?

 No, not without talking to your doctor first. Vitruvias and the FDA both advise contacting your healthcare provider for guidance or a replacement prescription rather than stopping cold.

What symptoms should I watch for from superpotent thyroid tablets?

 Weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, or heart rhythm disturbances. Contact your doctor if any of these appear after taking this medication.

Has anyone been harmed by the recalled thyroid tablets?

 Vitruvias Therapeutics reported no adverse events connected to this recall as of the August 21, 2026, announcement. That doesn’t rule out unreported cases — anyone experiencing symptoms should contact their doctor and can report the issue to the FDA’s MedWatch program.

Is there a lawsuit against Vitruvias Therapeutics over this recall?

 Not as of this writing. This is a voluntary recall, not litigation. If documented injuries emerge, a product liability attorney can evaluate whether a claim is warranted.

How many of the recalled tablets were actually sold to patients?

 Vitruvias released 3,655 units from Lot 504950 and reported 1,955 of those were sold, distributed nationwide between January 31, 2025, and September 30, 2025.

Sources Used in This Article

• Vitruvias Therapeutics, Inc., FDA Company Announcement, published August 24, 2026 (announcement dated August 21, 2026): https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential

Researched and written by Israr Ahmad, legal content researcher and founder of AllAboutLawyer.com. All facts verified against the FDA’s published company announcement for Vitruvias Therapeutics, Inc., as of August 26, 2026. Last Updated: August 26, 2026.

This article is for informational purposes only and does not constitute legal or medical advice. Laws vary by state and individual circumstances differ. For advice about your specific situation, consult a qualified attorney or healthcare provider.